KR860000279A - 1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산의 제조방법 - Google Patents

1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산의 제조방법 Download PDF

Info

Publication number
KR860000279A
KR860000279A KR1019850003854A KR850003854A KR860000279A KR 860000279 A KR860000279 A KR 860000279A KR 1019850003854 A KR1019850003854 A KR 1019850003854A KR 850003854 A KR850003854 A KR 850003854A KR 860000279 A KR860000279 A KR 860000279A
Authority
KR
South Korea
Prior art keywords
oxo
hydrogen
piperazinyl
cyclopropyl
dihydro
Prior art date
Application number
KR1019850003854A
Other languages
English (en)
Inventor
페터슨 우베 (외 3)
Original Assignee
루디 마이어, 요아힘 그렘
바이엘악티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루디 마이어, 요아힘 그렘, 바이엘악티엔 게젤샤프트 filed Critical 루디 마이어, 요아힘 그렘
Publication of KR860000279A publication Critical patent/KR860000279A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기 일반식(Ⅰ)으로 표시되는 1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산류 및 약물학적으로 이용 가능한 그 수화물, 알칼리 금속 및 알칼리토금속염류.
    (Ⅰ)
    상기 식중, R1는 수소, 메틸 또는 에틸이고, R2는 수소 또는 불소이다.
  2. 1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-4-퀴놀린카르복실산
  3. 1-시클로프로필-6,8-디플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산
  4. 하기 일반식(Ⅰ)으로 표시되는 1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산류 및 약물학적으로 이용가능한 그 수화물, 알칼리 금속 및 알칼리토금속염류.
    (Ⅰ)
    상기 식중 R1은 수소, 메틸 또는 에틸이고, R2는 수소 또는 불소이다.
  5. 하기 일반식(Ⅰ)으로 표시되는 질병치료용 1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산류 및 약물학적으로 이용 가능한 그 수화물, 알칼리금속 및 알칼리토금속 염류.
    (Ⅰ)
  6. 하기 일반식(Ⅰ)으로 표시되는 1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산류 및 약물학적으로 이용 가능한 그 수화물, 알칼리금속 및 알칼리토금속 염류를 함유하는 의약품
    (Ⅰ)
    상기 식중, R1는 수소, 메틸 또는 에틸이고, R2는 수소 또는 불소이다.
  7. 하기 일반식(Ⅰ)으로 표시되는 1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산류 및 약물학적으로 이용 가능한 그 수화물, 알칼리 금속 및 알칼리토금속 염류를 비활성이고 무독성이며, 약물학적으로 적합한 부형제와 혼합시킴을 특징으로 하는 의약품의 제제방법.
    (Ⅰ)
    상기 식중, R1는 수소, 메틸 또는 에틸이고, R2는 수소 또는 불소이다.
  8. 하기 일반식(Ⅲ)의 화합물을 일반식(Ⅲ)의 2-피페라지논과 반응시킴을 특징으로 하는 하기 일반식(Ⅰ)의 1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소 -7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산의 제조방법
    (Ⅱ)
    (식중,R2는 수소 또는 불소이고, X는 염소,브롬 또는 불소임)
    (Ⅲ)
    (식중, R1는 수소, 메틸 또는 에틸임)
    (Ⅰ)
    (식중, R1및 R2는 상기 정의한 바와 같음).
  9. 제8항에 있어서, 상기 반응을 디메틸 술폭사이드, N,N-디메틸포름아미드, 헥사메틸포스포릭 트리스아미드,술폴란,물,알코올(예,메탄올,에탄올,n-프로판올 또는 이소프로판올)중에서 행하거나, 또는 글리콜 모노메틸에테르 또는 피리딘 중에서 행함을 특징으로하는 방법.
  10. 제8항 및 제9항에 있어서, 상기 반응은 20°-200℃의 온도와 약 1-10기압(1-10bar)의 압력하에서 행함을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019850003854A 1984-06-04 1985-06-03 1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산의 제조방법 KR860000279A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3420770.8 1984-06-04
DE19843420770 DE3420770A1 (de) 1984-06-04 1984-06-04 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7-(3-oxo-1-piperazinyl)-3-chinoloncarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel

Publications (1)

Publication Number Publication Date
KR860000279A true KR860000279A (ko) 1986-01-27

Family

ID=6237581

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850003854A KR860000279A (ko) 1984-06-04 1985-06-03 1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산의 제조방법

Country Status (11)

Country Link
US (1) US4588726A (ko)
EP (1) EP0166939B1 (ko)
JP (1) JPS611682A (ko)
KR (1) KR860000279A (ko)
AT (1) ATE35264T1 (ko)
CA (1) CA1248953A (ko)
DE (2) DE3420770A1 (ko)
DK (1) DK249385A (ko)
ES (1) ES8607278A1 (ko)
IL (1) IL75367A (ko)
ZA (1) ZA854164B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3420116A1 (de) * 1984-05-30 1985-12-05 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
DE3509546A1 (de) * 1985-03-16 1986-09-25 Bayer Ag, 5090 Leverkusen 7-amino-1-(subst.cyclopropyl)-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
DE3705621C2 (de) * 1986-02-25 1997-01-09 Otsuka Pharma Co Ltd Heterocyclisch substituierte Chinoloncarbonsäurederivate
US5591744A (en) * 1987-04-16 1997-01-07 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US5262417A (en) * 1988-12-06 1993-11-16 The Upjohn Company Antibacterial quinolone compounds
US4992449A (en) * 1990-02-01 1991-02-12 American Cyanamid Company 7-(substituted)cycloalkylamino-1-(substituted)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids
JP2613139B2 (ja) * 1990-07-19 1997-05-21 エスエス製薬 株式会社 キノロンカルボン酸誘導体
DE4301247A1 (de) * 1993-01-19 1994-07-21 Bayer Ag Verfahren zur Herstellung mehrfach halogenierter Benzotrichloride und Benzoylchloride sowie neue Trihalogenbenzotrichloride und -benzoylchloride
NZ287550A (en) * 1994-07-18 1998-01-26 Ube Industries 8-trifluoromethylquinolinecarboxylic acid derivatives; medicaments
DE19503471A1 (de) * 1995-02-03 1996-08-08 Bayer Ag Verfahren zur Herstellung von kernhalogenierten Benzoylchloriden
IN186245B (ko) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
CN101851164A (zh) * 2010-05-28 2010-10-06 南京大唐医药科技有限公司 取代的含氟,氮类苯甲酰乙酸乙酯的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5845426B2 (ja) * 1978-09-29 1983-10-08 杏林製薬株式会社 置換キノリンカルボン酸誘導体
DE3033157A1 (de) * 1980-09-03 1982-04-01 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-naphthyridin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
SE440354B (sv) * 1981-02-19 1985-07-29 Kyorin Seiyaku Kk Kinolinkarboxylsyraderivat
DE3248506A1 (de) * 1982-12-29 1984-07-05 Bayer Ag, 5090 Leverkusen 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7(alkyl-1-piperazinyl)-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
DE3306771A1 (de) * 1983-02-25 1984-08-30 Bayer Ag, 5090 Leverkusen Chinoloncarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel

Also Published As

Publication number Publication date
ATE35264T1 (de) 1988-07-15
EP0166939B1 (de) 1988-06-22
DK249385A (da) 1985-12-05
EP0166939A1 (de) 1986-01-08
ZA854164B (en) 1986-01-29
US4588726A (en) 1986-05-13
DK249385D0 (da) 1985-06-03
JPS611682A (ja) 1986-01-07
CA1248953A (en) 1989-01-17
DE3420770A1 (de) 1985-12-05
DE3563441D1 (en) 1988-07-28
ES543837A0 (es) 1986-06-01
IL75367A (en) 1988-09-30
IL75367A0 (en) 1985-09-29
ES8607278A1 (es) 1986-06-01

Similar Documents

Publication Publication Date Title
KR860000279A (ko) 1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-7-(3-옥소-1-피페라지닐)-3-퀴놀린카르복실산의 제조방법
KR860004026A (ko) 알킬-1-시클로프로필-1,4-디히드로-4-옥소-3-퀴놀린 카르복실산의 제조방법
KR840000525A (ko) 1-사이클로프로필-6-플루오로-1,4-디하이드로-4-옥소-7-피페라지노-퀴놀린-3-카복실산의 제조방법
US5958955A (en) Method for the synthesis of a benzimidazole compound
NZ207239A (en) Quinolone carboxylic acid derivatives and pharmaceutical compositions
JPS6239566A (ja) 化学方法
CA1256878A (en) Benzimidazol derivatives and their production
KR860000280A (ko) 7-(3-아릴-1-피페라지닐)-및 7-(3-시클로헥실-1-피페닐지닐)-3-퀴놀론카르복실산의 제조방법
KR930000503A (ko) 7-이소인돌리닐-퀴놀론- 및 -나프티리돈카르복실산 유도체
KR860001070A (ko) 할로겐화 퀴놀론 카복실산의 제조방법
JPS633857B2 (ko)
KR860007244A (ko) 퀴놀린 카복실산 유도체의 제조방법
EP0351889B1 (en) Process for the preparation of a quinoline carboxylic acid
JP2693988B2 (ja) キノリンカルボン酸誘導体の製造方法
KR860003239A (ko) 퀴놀론 카복실산 유도체의 제조방법
IL39672A (en) Pyrimidine derivatives and their preparation
EP0309537A1 (en) PROCESS FOR THE PREPARATION OF QUINOLINE CARBOXYLIC ACIDS.
JPS6129354B2 (ko)
Anderson et al. 2-Aryl-3-acetyl-4 (1H)-quinolones1
KR0146335B1 (ko) 퀴놀린 카르복실산 유도체의 제조방법
NO177748B (no) Fremgangsmåte for å redusere en karbonylinneholdende acridin
JPS6479168A (en) Novel synthesis of 6,5-diacyl-7-deacetylforskolin derivative and intermediate
US3644392A (en) 1-substituted-5-nitroimidazole-2-carboximidates
JP2957273B2 (ja) ７―クロル―キノリン―８―カルボン酸の精製方法
KR900002041B1 (ko) 퀴놀론 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application